WebIpsen has an agreement in place to acquire oncology specialist Epizyme for $247 million. The primary target in the deal is lymphoma drug Tazverik WebAug 9, 2024 · Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious …
EPZM Stock Forecast, Price & News (Epizyme) - MarketBeat
WebJun 27, 2024 · Join Mergr to view all 269 acquisitions of life science companies in 2024, including 23 acquisitions by private equity firms, and 246 by strategics. Acquired by Ipsen SA (Company) on 2024-06-27 Epizyme Epizyme, Inc. 400 Technology Square 4th Floor, Cambridge, Massachusetts 02139 United States, (617) 229-5872 www.epizyme.com … Webwww.epizyme.com Ownership Status Acquired/Merged Financing Status Formerly VC-backed Primary Industry Drug Discovery Other Industries Pharmaceuticals Biotechnology Acquirer Ipsen Group Primary Office 400 Technology Square 4th Floor Cambridge, MA 02139 United States Want detailed data on 3M+ companies? What you see here scratches the … find gigs in your area
EX-99.3 - SEC
WebNov 18, 2024 · Nov. 18, 2024 11:30 UTC. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and ... WebAug 12, 2024 · As part of the transaction, Ipsen acquires Epizyme's lead medicine, Tazverik ® (tazemetostat), a first-in-class, chemotherapy-free EZH2 a inhibitor, which was granted Accelerated Approval by the ... WebJun 27, 2024 · News • Jul 1, 2024. Capital Finance — Ipsen acquires US biotech Epizyme for $247 million. News • Jun 27, 2024. Epizyme, Inc. — Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology. News • Jun 27, 2024. markets.businessinsider.com — Ipsen To Acquire Epizyme For $1.45/share In Cash - Quick Facts. News • Jun 27, 2024. find gigs ottawa